



Lead Drug Candidate

CRV431, a cyclophilin inhibitor

NASH

- Severe form of fatty liver disease affects about 17 million people in the US
- *No approved drugs* for treatment of NASH
- May result in liver cirrhosis, liver transplant, liver cancer, death
- Huge market potential projected to reach \$54 Billion USD by 2027

Anticipated Events

2021

JULY

Reporting of top line data from Phase 2a clinical trial

Q3/Q4

Initiation of Phase 2b

Clinical events expected to propel value proposition of HEPA

Financials

CASH ON HAND

\$115.4 M

as of 3/31/21

SHARES

76.2 M

APPROX. BURN RATE PER QUARTER

\$5-6 M

will increase as Phase 2b NASH trial progress is made

Enough cash on hand to cover all costs of programs through end of Phase 2b (about 3 years in cash), assuming no expansion into other areas/projects

Intellectual Property

- Patents issued and many pending on chemical composition, utility, formulation
- Global prosecution of patents

Experienced Team

Research and Development Team

Hepion's current R&D team is same team that discovered and developed voclosporin (Lupkynis) and voclosporin commercial formulation, currently used in the treatment of lupus nephritis, while at Isotechnika (Aurinia Pharmaceuticals, NASDAQ:AUPH).

The core R&D team has collectively greater than 100 years of experience with cyclophilin inhibition drug development and discovered Hepion's platform of cyclophilin inhibitors, of which CRV431 is the lead molecule.

CEO - Robert Foster, PharmD, PhD

Founded Isotechnika (Aurinia) in June 1993, and served the company, mostly as CEO and Chairman, until 2014. Dr. Foster joined HEPA in 2016 as CSO and became company's CEO in 2018.

CFO - John Cavan

Formerly of Pine Hill, Stemline, Aegerion, AlgoRx, Alpharma, Sony, American Express and International Specialty Products, joined HEPA in 2016.

Chief Medical Officer - Todd Hobbs, MD

Formerly Chief Medical Officer of Novo Nordisk, joined HEPA in 2021.

CSO - Daren Ure, PhD

Post-doc at Mayo Clinic, joined Isotechnika (Aurinia) in 2003 and joined HEPA in 2016.

SVP, Drug Development - Daniel Trepanier, PhD

Joined Isotechnika (Aurinia) in 1997 and joined HEPA in 2016.

SVP, Clinical Pharmacology - Patrick Mayo, PhD

Joined Isotechnika (Aurinia) in early 2000s and joined HEPA in 2019.